Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

A Stable Nano-Vaccine for the Targeted Delivery of Tumor-Associated Glycopeptide Antigens

Kevin R. Trabbic, Kristopher A. Kleski, Joseph J Barchi Jr.
doi: https://doi.org/10.1101/2021.04.27.438445
Kevin R. Trabbic
Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristopher A. Kleski
Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph J Barchi Jr.
Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: barchij@mail.nih.gov
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

Abstract

We have developed a novel antigen delivery system based on polysaccharide-coated gold nanoparticles (AuNPs) targeted to antigen presenting cells (APCs) expressing Dectin-1. AuNPs were synthesized de-novo using yeast-derived β-1,3-glucans (B13Gs) as the reductant and passivating agent in a microwave-catalyzed procedure yielding highly uniform and serum-stable particles. These were further functionalized with both peptides and glycopeptides from the tandem repeat sequence of mucin 4 (MUC4), a glycoprotein overexpressed in pancreatic tumors. The glycosylated sequence contained the Thomsen-Friedenreich disaccharide, a pan-carcinoma, Tumor-Associated Carbohydrate Antigen (TACA), which has been a traditional target for antitumor vaccine design. These motifs were prepared with a cathepsin B protease cleavage site (Gly-Phe-Leu-Gly), loaded on the B13Gs-coated particles and these constructs were examined for Dectin-1 binding, APC processing and presentation in a model in vitro system and for immune responses in mice. We showed that these particles elicit strong in vivo immune responses through the production of both high-titer antibodies and priming of antigen-recognizing T-cells. Further examination showed that a favorable antitumor balance of expressed cytokines was generated, with limited expression of immunosuppressive Il-10. This system is modular in that any range of antigens can be conjugated to our particles and efficiently delivered to APCs expressing Dectin-1.

Competing Interest Statement

The authors have declared no competing interest.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Back to top
PreviousNext
Posted April 28, 2021.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A Stable Nano-Vaccine for the Targeted Delivery of Tumor-Associated Glycopeptide Antigens
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A Stable Nano-Vaccine for the Targeted Delivery of Tumor-Associated Glycopeptide Antigens
Kevin R. Trabbic, Kristopher A. Kleski, Joseph J Barchi Jr.
bioRxiv 2021.04.27.438445; doi: https://doi.org/10.1101/2021.04.27.438445
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
A Stable Nano-Vaccine for the Targeted Delivery of Tumor-Associated Glycopeptide Antigens
Kevin R. Trabbic, Kristopher A. Kleski, Joseph J Barchi Jr.
bioRxiv 2021.04.27.438445; doi: https://doi.org/10.1101/2021.04.27.438445

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Immunology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4662)
  • Biochemistry (10317)
  • Bioengineering (7646)
  • Bioinformatics (26259)
  • Biophysics (13485)
  • Cancer Biology (10653)
  • Cell Biology (15371)
  • Clinical Trials (138)
  • Developmental Biology (8470)
  • Ecology (12782)
  • Epidemiology (2067)
  • Evolutionary Biology (16800)
  • Genetics (11373)
  • Genomics (15435)
  • Immunology (10585)
  • Microbiology (25093)
  • Molecular Biology (10175)
  • Neuroscience (54257)
  • Paleontology (399)
  • Pathology (1663)
  • Pharmacology and Toxicology (2884)
  • Physiology (4329)
  • Plant Biology (9216)
  • Scientific Communication and Education (1583)
  • Synthetic Biology (2545)
  • Systems Biology (6764)
  • Zoology (1459)